

Press Releases

All Years ▾
<input type="text" value="Search"/>
<input type="button" value="Go"/>

[Advanced Search](#)

MAY 9, 2019

[Perrigo To Expand Into Adjacent Self-Care Category By Acquiring Ranir Global Holdings LLC, The Leading Global Private Label Supplier Of Oral Self-Care Products](#)

- All cash transaction valued at \$750 million, or approximately \$685 million inclusive of cash tax benefits on a present value basis

MAY 8, 2019

[Perrigo Company plc Reports First Quarter 2019 Financial Results, Begins Consumer Self-Care Transformation](#)

MAY 8, 2019

[Perrigo To Divest Animal Health Business For \\$185 Million In Cash As Part Of Consumer Self-Care Transformation](#)

MAY 1, 2019

[Perrigo Announces First Quarter Calendar Year 2019 Earnings Date And Upcoming Conference Participation](#)

APR 26, 2019

[Perrigo Increases Its Dividend By 11%](#)

APR 18, 2019

[**Perrigo To Host Investor Day**](#)

APR 4, 2019

[**Perrigo Announces Tentative FDA Approval For The Generic Version Of Sernivo® Spray, 0.05%**](#)

APR 2, 2019

[**Perrigo Announces Patent Litigation Settlement For The Generic Version Of Finacea® Foam, 15%**](#)

MAR 20, 2019

[**Perrigo Appoints Seasoned CPG Veteran Ray Silcock As Chief Financial Officer**](#)

MAR 18, 2019

[**Perrigo Announces Tentative FDA Approval For The Generic Version Of Finacea® Foam, 15%**](#)

MAR 5, 2019

[**Perrigo Confirms Patent Challenge for Generic Version of Nascobal®**](#)

FEB 27, 2019

[**Perrigo Company plc Reports Fourth Quarter And Full-Year 2018 Financial Results**](#)

FEB 25, 2019

[**Perrigo Receives Leave To Judicially Review Irish Revenue Tax Assessment**](#)

[Assessment](#)

- Committed to vigorously challenge the Notice of Amended Assessment; believes it is without merit and incorrect as a matter of law

FEB 14, 2019

[Perrigo Announces Quarterly Dividend](#)

FEB 13, 2019

[Perrigo Announces Patent Litigation Settlement for the Generic Version of Jublia® Topical Solution 10%](#)

FEB 13, 2019

[Perrigo Company plc To Release Fourth Quarter And Calendar Year 2018 Results On February 27, 2019](#)

FEB 6, 2019

[Perrigo Announces FDA Final Approval for its AB Rated Generic Version of Zovirax® Cream 5%](#)

JAN 29, 2019

[Perrigo To Receive Milestone Payment Of \\$250 Million From RPI Finance Trust](#)

JAN 14, 2019

[Perrigo Appoints James Dillard To Role Of Chief Scientific Officer](#)

DEC 20, 2018

[Perrigo To Present At The J.P. Morgan Global Healthcare Conference](#)

DEC 10, 2018

[Perrigo Announces the Launch of an AB Rated Generic Version of Topicort® Topical Spray 0.25%](#)

NOV 28, 2018

[Perrigo Announces Patent Litigation Settlement For The Generic Version Of Sernivo® Spray, 0.05%](#)

NOV 27, 2018

[Perrigo Launches Its AB Rated Generic Version of Solaraze® Gel 3%](#)

NOV 26, 2018

[Perrigo Announces Tentative FDA Approval For The First To File Generic Version Of Ultravate® Lotion 0.05%](#)

NOV 8, 2018

[Perrigo Company plc Reports Third Quarter 2018 Financial Results](#)

OCT 31, 2018

[Perrigo Announces Quarterly Dividend](#)

OCT 29, 2018

[Perrigo Confirms Patent Challenge For Generic Version Of Kerydin®](#)

OCT 26, 2018

[Perrigo Confirms Patent Challenge For Generic Version Of Narcan®](#)

OCT 25, 2018

[Perrigo Announces the Launch of an AB Rated Generic Version of Ultravate® Lotion 0.05%](#)

Perrigo To Release Third Quarter Calendar Year 2018 Financial Results On November 8, 2018

OCT 15, 2018

Perrigo Announces The Launch Of An AB Rated Generic Version Of Androgel® Topical Gel, 1.62%

OCT 8, 2018

Perrigo Appoints Murray S. Kessler As President And Chief Executive Officer In Line With Shift To Consumer-Focused Strategy

OCT 1, 2018

Perrigo Confirms Patent Challenge for Generic Version of Jublia® Topical Solution 10%

SEP 28, 2018

Perrigo Announces Patent Litigation Settlement for the Generic Version of Picato® Gel

SEP 7, 2018

Perrigo Announces Final FDA Approval and Planned Launch for the Store Brand OTC Equivalent of Imodium® Multi-Symptom Relief

AUG 29, 2018

Perrigo to Reschedule Investor Event

AUG 9, 2018

Perrigo Expands OTC Growth Strategy With Rx-To-OTC Switch Licensing For Nasonex®

- Expands Consumer Healthcare Americas growth strategy with innovative offering for an Rx to OTC

- Expands Consumer Healthcare Americas growth strategy with innovative offering for an FX to OTC brand switch and store brand solution

AUG 9, 2018

[Perrigo Announces Plan To Separate Prescription Pharmaceuticals Business](#)

AUG 9, 2018

[Perrigo Company plc Reports Second Quarter 2018 Financial Results](#)

AUG 1, 2018

[Perrigo Announces Quarterly Dividend](#)

JUL 26, 2018

[Perrigo To Release Second Quarter Calendar Year 2018 Financial Results On August 9, 2018](#)

MAY 30, 2018

[Perrigo to Present at the Jefferies 2018 Healthcare Conference](#)

MAY 24, 2018

[Perrigo Confirms Patent Challenge For Generic Version Of Sernivo® Spray, 0.05%](#)

MAY 14, 2018

[Perrigo Confirms First To File Patent Challenge For Generic Version Of Ultravate® Lotion, 0.05%](#)

MAY 11, 2018

[Perrigo Expects Complete Response Letter On Generic Version Of ProAir®](#)

MAY 8, 2018

[Perrigo Company plc Reports First Quarter 2018 Financial Results](#)

MAY 3, 2018

[Perrigo Announces Quarterly Dividend](#)

APR 24, 2018

[Perrigo To Release First Quarter Calendar Year 2018 Financial Results On May 8, 2018](#)

- Separately, the Company announced that it will present at the Deutsche Bank Healthcare Conference on May 9, 2018

APR 11, 2018

[Perrigo Launches Novel Omeprazole Orally Disintegrating Tablet to Treat Frequent Heartburn](#)

- Consumer friendly dosing provides patients with needed heartburn alternative

MAR 7, 2018

[Perrigo Announces Final FDA Approval and Planned Launch for the Store Brand OTC Equivalent of Mucinex® DM Maximum Strength Extended Release Tablets](#)

MAR 7, 2018

[Perrigo to Present at Upcoming Investor Conferences](#)

MAR 1, 2018

[Perrigo Files Form 10-K With SEC With FY17 Financials](#)

[Perrigo Files Form 10-K With SEC; Will Host Fourth Quarter And Calendar Year 2017 Financial Results Conference Call On March 2, 2018](#)

MAR 1, 2018

[Perrigo Company plc Reports Fourth Quarter & Calendar Year 2017 Financial Results](#)

FEB 27, 2018

[Perrigo Company plc Reports Select Preliminary Unaudited Calendar Year 2017 Financial Results](#)

Will reschedule its fourth quarter and fiscal year 2017 final earnings release and conference call, previously scheduled for Tuesday, February 27, 2018

FEB 20, 2018

[Perrigo Confirms Patent Challenge For Generic Version Of Finacea® Foam, 15%](#)

FEB 20, 2018

[Perrigo Appoints Ronald L. Winowiecki as Chief Financial Officer](#)

FEB 15, 2018

[Perrigo Announces Quarterly Dividend](#)

FEB 8, 2018

[Perrigo To Release Fourth Quarter And Calendar Year 2017 Financial Results On February 27, 2018](#)

JAN 30, 2018

[Perrigo Announces Tentative FDA Approval For The Generic Version Of Soolantra® Cream. 1%](#)

JAN 26, 2018

[Perrigo Announces Tentative FDA Approval For The Generic Version Of Onexton® Gel](#)

JAN 24, 2018

[Perrigo Announces Final FDA Approval Of A Generic Version Of Estrace® Cream](#)

JAN 24, 2018

[Perrigo Announces Final FDA Approval And Launch Of An AB Rated Generic Version Of Epiduo® Gel](#)

JAN 8, 2018

[Perrigo Appoints Uwe Röhrhoff As President & Chief Executive Officer](#)

- Uwe Röhrhoff, former Chief Executive Officer at Gerresheimer AG, appointed President, CEO and board member effective January 15, 2018

JAN 3, 2018

[Perrigo Announces Tentative FDA Approval For The Generic Version Of Prolensa® Ophthalmic Solution 0.07%](#)

JAN 2, 2018

[Perrigo To Present At The 36th Annual J.P. Morgan Healthcare Conference](#)

NOV 27, 2017

[Perrigo Announces the Launch of an AB Rated Generic Version of Mycolog® II Cream](#)

NOV 27, 2017

[Perrigo Announces the Launch of an AB Rated Generic Version of Exalgo® 32mg Extended Release Tablets](#)

NOV 21, 2017

[Perrigo Company Completes Divestiture Of API Business For \\$110 Million](#)

NOV 10, 2017

[Perrigo Company to Present at the Stifel 2017 Healthcare Conference](#)

NOV 9, 2017

[Perrigo Company plc Reports Third Quarter 2017 Financial Results](#)

NOV 2, 2017

[Perrigo Company plc Announces Quarterly Dividend](#)

NOV 2, 2017

[Perrigo Announces Tentative FDA Approval for a First-to-File Generic Version of Picato® Gel 0.05%](#)

OCT 26, 2017

[Perrigo To Release Third Quarter 2017 Financial Results On November 9, 2017](#)

OCT 26, 2017

[Perrigo Announces Patent Litigation Settlement for the Generic Version](#)

[of Unexton® Gel](#)

OCT 24, 2017

[Perrigo Announces Tentative FDA Approval For A First-To-File Generic Version Of Picato® Gel .015%](#)

SEP 27, 2017

[Perrigo Announces First-To-Market Launch Of The OTC Store Brand Equivalent Of Nexium® 24HR Capsules](#)

SEP 21, 2017

[Perrigo Announces FDA Final Approval For Its AB Rated Generic Version Of Exalgo® 32mg Extended Release Tablets](#)

SEP 18, 2017

[Perrigo Announces Tentative FDA Approval For The Generic Version Of Acanya® Gel](#)

AUG 30, 2017

[Perrigo Company To Present At Upcoming Investor Conferences](#)

AUG 21, 2017

[Perrigo Announces Final FDA Approval And Settlement For The Store Brand OTC Equivalent Of Nexium® 24HR Capsules](#)

AUG 16, 2017

[Perrigo Announces FDA Final Approval for its AB Rated Generic Version of Mycolog® II Cream](#)

AUG 10, 2017

[Perrigo Company plc Reports Second Quarter 2017 Financial Results](#)

AUG 8, 2017

[Perrigo Company plc Announces Quarterly Dividend](#)

AUG 4, 2017

[Perrigo Announces Tentative FDA Approval For Generic Version Of Mirvaso® Gel](#)

JUL 31, 2017

[Perrigo Announces The Launch Of The AB Rated Generic Version Of Transderm Scop® 1.5 mg](#)

JUL 27, 2017

[Perrigo To Release Second Quarter 2017 Financial Results On August 10, 2017](#)

JUL 19, 2017

[Perrigo Announces FDA Final Approval For Its AB Rated Generic Version Of DermOtic® Oil, 0.01% Ear Drops](#)

JUL 17, 2017

[Perrigo Confirms Patent Challenge For Generic Version Of Soolantra® Cream, 1%](#)

JUL 17, 2017

[Perrigo Announces FDA Final Approval For Its First-To-File Ab Rated Generic Version Of AndroGel® Topical Gel, 1.62% Packets](#)

JUL 17, 2017

[Perrigo Announces Settlement Of Generic Version Of Dymista® Nasal Spray Patent Litigation](#)

JUL 5, 2017

[Perrigo Launches The Generic Version Of Axiron® Topical Solution](#)

JUN 21, 2017

[Perrigo Company Retains Spencer Stuart for CEO Search](#)

JUN 21, 2017

[Perrigo Announces the Launch of Generic Equivalents to Derma-Smoothe/FS® Scalp Oil and Body Oil](#)

JUN 19, 2017

[Perrigo Announces the Launch of Hydrocodone Bitartrate and Homatropine Methylbromide Oral Solution](#)

JUN 14, 2017

[Perrigo Company plc Announces Pricing for its Cash Tender Offer](#)

JUN 14, 2017

[Perrigo Company To Present At The 17th Annual Oppenheimer Consumer Conference](#)

JUN 14, 2017

[Perrigo Company plc Announces Early Tender Results for Cash Tender](#)

[Offer](#)

JUN 5, 2017

[Perrigo Announces Forthcoming Retirement Of CEO John Hendrickson](#)

JUN 2, 2017

[Perrigo Company To Present At The Jefferies 2017 Healthcare Conference](#)

MAY 31, 2017

[Perrigo Company plc Announces \\$1,400,000,000 Cash Tender Offer for Certain Notes](#)

MAY 30, 2017

[Perrigo To Conduct Conference Call On May 31, 2017 At 8:30 AM ET](#)

Show per page

[«](#) [1](#) [2](#) [3](#) [4](#) [5](#) [6](#) [7](#) [8](#) [9](#) [10](#) [»](#)



<https://investor.perrigo.com/press-releases?l=100&o=200>